Ashok Ganguly - Dr Reddys Non-Executive Independent Director

RDY -- USA Stock  

USD 38.37  0.41  1.06%

Dr. Ashok Sekhar Ganguly is NonExecutive Independent Director of Dr. Reddy Laboratories Ltd. He joined our Board in 2009. He is currently the Chairman of ABP Private Ltd. . He was the Chairman of Hindustan Lever Ltd. from 1980 to 1990 and member of the Unilever Plc Board from 1990 to 1997. He was an Independent Director of British Airways from 1996 to 2005. He was a Director on the Central Board of Reserve Bank of India from 2001 to 2009. He also serves as a Director on the Board of Wipro Ltd. He is a recipient of the Padma Bhushan as well as Padma Vibhushan, two of Indias prestigious civilian honors and a CBE from the UK. He was also a member of the Rajya Sabha, the upper house of the Parliament of India, from 18 November 2009 to 17 November 2015.
Age: 79  Director Since 2009  Ph.D    
91 40 4900 2900
Ashok S Ganguly joined the Company?s Board in 2009. He is currently the Chairman of ABP Private Limited and was a Director on the Central Board of Reserve Bank of India from 2001 to 2009. He is a member of the Prime Minister?s Council on Trade and Industry as well as the Investment Commission, and the IndiaUSA CEO Council set up by the Prime Minister of India and the President of the US. He is also a member of the National Knowledge Commission to the Prime Minister of India. He was the Chairman of Hindustan Lever Limited from 1980 to 1990, and member of the Unilever Board from 1990 to 1997 with responsibility for worldwide research and technology. He also serves as a nonExecutive Director of Mahindra & Mahindra and Wipro Limited and as a member of Advisory Board of Diageo India Pvt. Limited. He is a recipient of the ?Padma Bhushan? as well as ?Padma Vibhushan?, two of India?s prestigious civilian honours

Management Efficiency

The company has Return on Asset of 5.42 % which means that on every $100 spent on asset it made $5.42 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.08 % implying that it generated $15.08 on every 100 dollars invested.
The company has 811.73M in debt with debt to equity (D/E) ratio of 23.5 . This implies that the company may be unable to create cash to meet all of its financial commitments. Dr Reddys Laboratories has Current Ratio of 1.85 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives


Willie ReedZoetis
Christine PoonRegeneron Pharmaceuticals
Laurie BrlasPerrigo Company plc
Alan GarberVertex Pharmaceuticals Incorpor
David AltshulerVertex Pharmaceuticals Incorpor
Theodore SamuelsPerrigo Company plc
Fei WangOrigin Agritech Limited
Bradley AlfordPerrigo Company plc
Gregory NordenZoetis
Geoffrey ParkerPerrigo Company plc
Huda ZoghbiRegeneron Pharmaceuticals
Lloyd CarneyVertex Pharmaceuticals Incorpor
Donal OConnorPerrigo Company plc
Arthur RyanRegeneron Pharmaceuticals
Margaret McGlynnVertex Pharmaceuticals Incorpor
Ellen HoffingPerrigo Company plc
Herman MorrisPerrigo Company plc
Theodore SamuelstoPerrigo Company plc
Min TangOrigin Agritech Limited
William YoungVertex Pharmaceuticals Incorpor
Elaine UllianVertex Pharmaceuticals Incorpor

Entity Summary

Reddys Laboratories Limited operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 21966 people.Dr Reddys Laboratories Ltd (RDY) is traded on BATS Exchange in USA and employs 21,966 people.

Dr Reddys Laboratories Leadership Team

G Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing Director
MARC KIKUCHI, Chief Executive Officer, North America Generics
Hans Hasler, Additional Independent Director
Leo Puri, Non-Executive Independent Director
Sandeep Poddar, Compliance Officer, Company Secretary
Satish Reddy, Co-Chairman of the Board
Kedar Upadhye, IR Contact Officer
Samiran Das, Executive Vice President Head - FTO and GGPM
Sauri Gudlavalleti, Global Head of Integrated Product Development Organization
YUGANDHAR PUVVALA, Global Head of Supply Chain
Amit Biswas, Executive Vice President - Integrated Product Development
Ravi Bhoothalingam, Non-Executive Independent Director
Alok Sonig, Senior Vice President & India Business Head (Generics)
Allan Oberman, Non-Executive Independent Director
J Ramachandran, Executive Vice President-Management Systems and Corporate Initiatives
Prasad Menon, Lead Non-Executive Independent Director
K Rao, Sr. Vice President & Head ? Chemical Technical Operations (CTO)
Abhijit Mukherjee, COO
Anil Namboodiripad, Global Head of Proprietary Products
Saumen Chakraborty, President, Chief Financial Officer and Global Head of ITBPE, Legal & Compliance and FMCRE
SANJAY SHARMA, Global Head of Manufacturing
Shikha Sharma, Non-Executive Independent Director
Sridar Iyengar, Non-Executive Independent Director
Ganadhish Kamat, Executive Vice President and Global Head-Quality
Sripada Chandrasekhar, President, Global Head of HR and Member of Management Council
Omkar Goswami, Non-Executive Independent Director
Erez Israeli, Chief Operating Officer and Global Head of Generics & PSAI
Kalpana Morparia, Non-Executive Independent Director
Bharat Doshi, Non-Executive Independent Director
J Moreau, Non-Executive Independent Director
Raymond Vre, Global Head of Biologics
Raghav Chari, Senior Vice President - Proprietary Products
Bruce Carter, Non-Executive Independent Director
Saunak Savla, IR Contact Officer
Ashok Ganguly, Non-Executive Independent Director
Umang Vohra, Executive Vice President Head - North America Generics
M Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets)
Cartikeya Reddy, Senior Vice President Head - Biologics
Anupam Puri, Non-Executive Independent Director
Archana Bhaskar, Chief Human Resource Officer
Deepak Sapra, Global Head of PSAI

Stock Performance Indicators

Did you try this?

Run Piotroski F Score Now


Piotroski F Score

Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
All  Next Launch Module

Currently Active Assets on Macroaxis

Purchased over 20 shares of
1 hour ago
Traded for 135.34
Purchased a lot of shares of
1 hour ago
Traded for 155.87
Purchased over 70 shares of
1 hour ago
Traded for 35.56
Purchased few shares of
1 hour ago
Traded for 174.95
Purchased a lot of shares of
1 hour ago
Traded for 153.01
Additionally take a look at Your Equity Center. Please also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. drill down to check world indexes.